GryeOx addresses significant unmet need in drug discovery as the IP can make expanded drug libra of macrocycles in the hit to lead stage.

DNA assembly.

"CRIS" software that enables submission, de-identification and sharing of mental health patient records using a federated data and information governance model.

Will develop optimisation codes for a number of sector, starting with the optimisation of nuclear fusion processes.

A biologics company with a mission to treat a range of autoimmune and inflammatory disorders.

Ion traps based quantum computing

Ion traps based quantum computing.

To develop compound libraries based on the asymmetric synthesis methodolofies.

Strategy gaming and consultancy

Will produce a new, scalable route to Cannabidiol.

OxStem Immuno aims to develop small molecule drugs that augment macrophage efferocytosis in
vitro and enhance tissue repair in vivo. These therapies will supercede the need for cell transplantation
or cytokine therapy in the context of tissue repair for chronic wounds and a range of inflammatory
conditions.

OxStem Beta will generate novel therapies to stimulate formation of new beta cells in the pancreas
(neogenesis) by targeting pathways that are normally only active during development or following
pancreatic injury.

A not for profit company providing a solution and accreditation to businesses that work to bring their workforce out of multidimensional poverty

Software and patented approach to differential diagnosis of cognitive diseases

Developing a brain implant to treat a variety of diseases.

LED spin-out using Perovskite technology.

Development and application of bacterial biosensors for detection and quantification of environmental contamination, including organics and metals, on-site and in real-time.

Company developing AI-based learning support applications.

A company being established to commercialise Zooniverse technology

Software development for a novel biomarker to detect coronary heart disease.